NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study
Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study

NCT05773196

UnknownN/A

Sponsor: Sanguine Biosciences

Conditions: Huntington Disease, Huntington's Dementia, Huntington Disease, Late Onset, Huntington; Dementia (Etiology)

Interventions: Biospecimen Collection

Countries: United States

OBJECTIVES: The primary study objective is to collect blood from participants with Huntington's Disease in order to validate a CE marked Cytosine, Adenine, Guanine (CAG) assay for use in future studies for Huntington's Disease. The secondary study objective is to create a biorepository that can be used to identify disease associated biomarkers and potential targets with immune and multi-omics profiling. The disease sample collection and analysis will be the foundation for an extensive network of biospecimen access and linked datasets for future translational research.

Eligibility overview

Sex: ALL

Age: 25 Years to 65 Years

Study type: OBSERVATIONAL

Eligibility criteria
Cohort 1: Huntington's Disease

Inclusion:

1. The participant is willing and able to provide written informed consent
2. The participant is willing and able to provide appropriate photo identification
3. Participants aged 25 to 65, inclusive
4. Participants have been diagnosed with Huntington's Disease
5. Patients must have numerical documentation of CAG repeats present in the Medical Record, along with a Huntington's Disease diagnosis.
6. Pre-existing evidence of CAG repeats should be in the range of 40-60 repeats \*Preference (not required for enrollment): Patients to have different CAG repeats from each other but this is not essential.\*

Exclusion:

1. Participants who are pregnant or are nursing
2. Participants with a known history of HIV, hepatitis, or other infectious diseases
3. Participants who have taken an investigational product in the last 30 days
4. Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months
Locations (1)
  • Woburn, Massachusetts, United States